Use of Alternative and Complementary Medicine by Colorectal Cancer Patients
Key facts
- Who runs it
- University Hospital, Limoges
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 217 people enrolled
- Started
- 20 Jan 2025
- Ended
- 10 Apr 2026
- Type of study
- Interventional
- Treatments tested
- Questionnaire CAM
- Record updated
- 29 June 2026
- Why it stopped
- Not enough awnser in the qualitative study
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Over 18 years of age
- Diagnosed with colorectal cancer
- To be operated on between 2017 and 2022
Who cannot take part
- Non-primary colorectal cancer (metastasis to the colon or rectum from another primary cancer; cancer originating in the appendix)
- Primary metastatic cancer other than colorectal cancer
- Discovery of cancer synchronous with colorectal cancer
- Cognitive disorders (Alzheimer's, dementia, etc.)
- Severe psychiatric disorder (neurodevelopmental disorder, psychotic disorder, mood disorder, etc.) according to the specific DSM-5 and ICD-11 classifications
- The patient refuses to give consent to participate in the study
- Guardianship or trusteeship
- Severe deafness (unable to answer questions during telephone interview)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Complementary and alternative medicine (CAM) is defined by the National Center for Complementary and Alternative Medicine as "a group of diverse medical and health systems, practices and products that are not currently considered part of conventional medicine" (Complementary, Alternative, or Integrative Health, n. d. 2012). Complementary medicine is used to complement conventional medicine, and alternative medicine is used instead of conventional medicine (Dy et al., 2004). These are two very different approaches, whose consequences for a cancer patient can be completely different. The use of CAM is steadily increasing in most countries. A study carried out in France in 2017 revealed that for half of CAM users, the diagnosis of cancer was one of the main factors that led patients to turn to CAM (Sarradon-Eck et al., 2017). CAM use was found to be significantly associated with younger age, female gender and higher education (Sarradon-Eck et al., 2017). The source of information about MAC was mainly friends/family and the media, while doctors and nurses played a succinct role in MAC information (Molassiotis et al., 2005). The most frequently cited reasons for using CAM were to improve their physical well-being, strengthen their bodies, improve their emotional well-being and relieve the side effects of treatment (Sarradon-Eck et al., 2020). Another study carried out in 2019 at nine centers in France showed that 45% of glioma patients had changed their eating habits after glioma diagnosis, 44% were on complementary treatment, mainly vitamins and dietary supplements, and 32% were using alternative medicine, mainly magnetism and acupuncture. A total of 68% reported using at least one of these approaches (Le Rhun et al., 2019). Another single-center study conducted in France in 2019 found that 83% of cancer patients used CAM (M et al., 2019). CAM included osteopathy, homeopathy, acupuncture, therapeutic touch, magnetism, naturopathy, cupping, Chinese medicine, reflexology and hypnosis. However, no studies have been carried out to assess the use of CAM among colorectal cancer (CRC) patients in France.
The group in the trial
- Complementary and alternative medicine userOther group
Selected patients will answer a questionnaire about their practice and habits with regard to alternative and complementary medicines. Of these patients, 12 will also complete an additional qualitative questionnaire.
Treatment: Questionnaire CAM
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 29 June 2026